![]() |
|
|
Vol. 301, Issue 2, 435-440, May 2002
Programmes in Lung Biology (R.P.J., X.L., V.H., A.K.T.) and Integrative Biology (P.D., R.A., C.R.P.-A.), Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada; Departments of Paediatrics (A.K.T.), Physiology (R.P.J., A.K.T.), and Pharmacology (C.R.P.-A.), Faculty of Medicine, University of Toronto, Ontario, Canada; and Department of Pediatrics (X.L.), Tongji Hospital and Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| |
Abstract |
|---|
|
|
|---|
Bleomycin has been suggested to incite plasma extravasation and influx of inflammatory cells leading to pulmonary fibrosis. We hypothesized that stable analogs of the 12-lipoxygenase product, hepoxilin, may attenuate these effects. We initially investigated the effects of the four hepoxilin analogs (PBT-1 to -4) coadministered intradermally with bleomycin and found that PBT-1 and -2 significantly opposed the vascular permeability effects of bleomycin in rat skin. We subsequently tested the hepoxilin analogs for their actions in opposing the intratracheal bleomycin-evoked acute inflammatory phase of lung fibrosis in the mouse, characterized by a marked accumulation of macrophages and an increase in the rate of collagen synthesis and deposition. We found that the bleomycin-evoked effects on macrophage influx were inhibited by all the hepoxilin analogs (PBT-1, -3, and -4 > PBT-2) administered i.p. for 8 days. Increased total lung collagen was completely abrogated by PBT-1 and -2, whereas PBT-3 and -4 had little effect. A dose-response study with PBT-1 indicated that the effective dose for inhibition of bleomycin-induced inflammatory and histological changes was below 10 µg/day. These studies demonstrate an in vivo action of stable analogs of hepoxilin and support an effect on inflammation and vascular permeability from these novel compounds, especially for PBT-1.
| |
Introduction |
|---|
|
|
|---|
Idiopathic
pulmonary fibrosis is a devastating disorder that is poorly understood
and resistant to treatment (Cooper, 2000
). The observation that the
antibiotic bleomycin sulfate (BL), a potent cancer chemotherapeutic
agent (Adamson, 1984
; Nici et al., 1998
), may cause interstitial lung
fibrosis in humans (Yagoda et al., 1972
) led to the development of
animal models in which a single dose of BL administered intratracheally
induced changes resembling human idiopathic pulmonary fibrosis
histopathologically (Kelley et al., 1980
). The acute phase of this
response is characterized by a marked accumulation of inflammatory
cells and an increase in the rate of collagen synthesis and deposition
(Cooper et al., 1988
; Gurujeyalakshmi and Giri, 1995
; Giri and
Hollinger, 1996
).
Previous animal studies have demonstrated that BL-evoked lung fibrosis
is exacerbated with nordihydroguaiaretic acid, a lipoxygenase inhibitor, suggesting that a lipoxygenase product may be involved in
endogenous mechanisms controlling lung fibrosis (Giri and Hollinger, 1996
). The hepoxilins (HXs) may be candidates for the control of lung
fibrosis as they are formed through the 12-lipoxygenase pathway of
metabolism of arachidonic acid (Pace-Asciak et al., 1983
; Pace-Asciak,
1984
; Pace-Asciak and Martin, 1984
). These compounds have previously
been shown to have significant biological actions (Pace-Asciak, 1984
;
Dho et al., 1990
; Laneuville et al., 1992
; Pace-Asciak et al., 1995
;
Reynaud et al., 1996
, 1999
; Sutherland et al., 2000
). HXs raise free
intracellular calcium in human neutrophils ex vivo through the release
from stores and vascular tissue in vitro and block the intracellular
calcium rise evoked by inflammatory mediators (Laneuville et al.,
1993
). HX formation is stimulated by inflammatory mediators in the skin
(Wang et al., 1999a
,b
) and in psoriasis (Anton and Vila, 2000
),
suggesting that they may be involved in anti-inflammatory mechanisms.
The present study was undertaken to determine whether stable analogs of
HX exhibit anti-inflammatory actions in vivo, first on BL-evoked
changes in skin vascular permeability followed by changes in the lung, using the well established, intratracheal, BL-induced pulmonary fibrosis mouse model (Kelley et al., 1980
).
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
HX analogs (PBT-1-PBT-4) were prepared as
previously described (Demin and Pace-Asciak, 1993
). BL, formamide,
hematoxylin, collagen type I, eosin, Evans blue, Fast Green FCF, and
picric acid-saturated solution were purchased from Sigma-Aldrich (St. Louis, MO); Direct Red 80 was obtained from Aldrich Chemical Co. (Milwaukee, WI), Sirius Red from Pfaltz and Bauer (Waterbury, CT),
enflurane from Zeneca Pharma (Mississauga, ON, Canada), and Inactin [ethyl-(1-methylpropyl)malonylthiourea] from BYK
Gulden (Constanz, Germany). Rat monoclonal antibody to murine
macrophage F4/80 antigen was purchased from BMA Biomedicals (Augst,
Switzerland). Goat anti-rat IgG-biotin was obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Avidin-biotin-peroxidase complex
immunohistochemistry kits were purchased from Vector Laboratories
(Burlingame, CA). Animals were obtained from Charles River
Canada(St. Constant, QC, Canada).
Institutional Review. All animal procedures were conducted according to criteria of the Canadian Council for Animal Care, and approval was obtained from the Animal Care Review Committee at The Hospital for Sick Children.
In Vivo Vascular Permeability.
Male Wistar rats (190-230 g)
were anesthetized with Inactin (120 mg/kg), and the dorsal area was
shaved. The trachea and left jugular vein were cannulated, and 35 mg/kg
Evans blue were administered i.v. 5 min prior to intradermal injections
of BL (12 µg in saline), BL + HX analogs (PBT-1-PBT-4) 100 ng in
saline, and HX analogs alone and saline alone. After 35 min, the
animals were decapitated, patches of skin containing the injection site
were punched out, weighed, and incubated in 3 ml of formamide at 70°C
in glass tubes. After 18 h, the tubes were cooled on ice and
centrifuged, and the supernatant was removed. The absorbance at 620 nm
was read spectrophotometrically (Laneuville et al., 1991
). The color
intensity was compared between BL alone to BL + HX analogs, saline + HX analogs, or saline alone.
Lung Injury and Interventions. Pulmonary fibrosis high-responder male CBA/J mice (28-30 g, 10 weeks old) were maintained under a controlled environment (temperature 24 ± 1°C, relative humidity 50-55%, 12-h light cycle). A total of 70 mice were studied. Under inhalational anesthesia with enflurane, animals received BL intratracheally (0.2 U in 50 µl of saline) or saline only (controls). The BL groups additionally received either saline or each of the four HX analogs (PBT-1, 10, 50, or 100 µg; and PBT-2-PBT-4, 100 µg each) in saline (100 µl) i.p. 1 day before BL administration and each day thereafter until sacrifice. Animals were sacrificed 7 days after BL administration.
Histology and Immunohistochemistry.
Animals were
anesthetized with intraperitoneal ketamine (80 mg/kg) and xylazine (20 mg/kg). The pulmonary circulation was flushed with phosphate-buffered
saline containing 1 U/ml heparin to clear the lungs of blood,
and perfusion was fixed with 4% (w/v) paraformaldehyde and 0.2% (v/v)
glutaraldehyde while a constant airway pressure of 10 cm of
H2O was maintained via a tracheal catheter. The
lungs were embedded in paraffin and cut in 5-µm sections. Sections
were mounted on
-aminopropyl-triethoxysilane-coated slides. Random
sections from all animals in each group were stained with H&E. Collagen
in the lung sections was stained with Sirius Red F3B (0.1%) and Fast
Green FCF (0.1%) in a saturated aqueous solution of picric acid
(Gascon-Barre et al., 1989
; Nagler et al., 1999
). Alveolar and
interstitial pulmonary macrophages were identified and counted by
immunohistochemistry on paraffin-embedded sections using an
avidin-biotin-peroxidase complex method (Hsu et al., 1981
) and then
counterstained with Carazzi hematoxylin, dehydrated, cleared in xylene,
and mounted. Dilutions of the primary and secondary antisera were 1:50
(4 µg/ml) and 1:250, respectively. Antibody specificity was verified
by omitting the primary antiserum. Macrophages were quantified by
counting positively stained cells per random high-power microscopic
field (four animals per group and average of four fields per animal).
Quantification of Lung Collagen.
Collagen content in lung
tissue was quantified by a sensitive spectrophotometric method (Marotta
and Martino, 1985
) utilizing precipitation of collagen with Sirius Red
in acetic acid solution. Absorbance values of the dye solution after
precipitation with collagen decrease linearly with increasing collagen
concentration. After sacrifice, the thoracic contents were removed en
bloc. The right lung was separated from the heart, airways, and major
pulmonary vessels and homogenized in 0.5 M acetic acid. The homogenate
was sonicated at 40 W for 30 s, left on ice for 30 min, and then
centrifuged at 1000g for 10 min to remove insoluble debris.
Samples (20 µl in 1 ml of 0.5 M acetic acid) and collagen type I
standards (0-500 µg/ml in 0.5 M acetic acid) were added
to an equal volume of Sirius Red (120 µg/ml) in 0.5 M
acetic acid. The mixture was left at room temperature for 30 min and
then centrifuged at 3000 rpm for 30 min. Absorbance of samples was
measured at 540 nm and plotted against standards with known
concentration of collagen type I.
Analysis of Data.
Values are expressed as the mean ± S.E.M. Statistical significance (p < 0.05) was
determined using Student's t test or one-way ANOVA with
assessment of differences using Duncan's multiple range test (Snedecor
and Cochran, 1980
).
| |
Results |
|---|
|
|
|---|
Evans blue dye leakage, as a marker of vascular permeability, was
quantified and compared between saline alone, BL in saline, and BL + HX
analogs (PBT-1-PBT-4) in saline, as shown in Fig. 1. A significant inhibition
(p < 0.05) of the BL-evoked plasma leakage was
observed with PBT-1 and PBT-2, which were comparable to saline alone,
whereas PBT-3 and PBT-4 had no effect relative to BL alone
(p > 0.05).
|
The histopathological changes from representative mice lung sections
stained with H&E are shown in Fig. 2. The
lung sections from BL-exposed animals showed severe lesions (Fig. 2B),
including diffuse alveolar hemorrhage, edema, and cellular infiltrate
in the alveolar space and interstitium, compared with saline-exposed controls (Fig. 2A). Treatment with PBT-1 (Fig. 2, C, D, and E) and
PBT-3 (Fig. 2G) markedly attenuated the BL-induced changes. The BL
effects were only partially improved in the lungs from groups treated
with the other HX analogs (Fig. 2, F and H).
|
Lung sections stained with Sirius Red for collagen are shown in Fig.
3. The sections from the BL-exposed,
saline-treated group (Fig. 3B) showed a marked increase in collagen
deposition around vessels and airways (stained red) compared with
saline-exposed controls (Fig. 3A). Similar to the improvements seen on
H&E staining, treatment with PBT-1 (Fig. 3, C, D, and E) significantly
opposed the BL effect, resulting in markedly reduced collagen content. The attenuation of BL-induced collagen deposition increased with increasing dose of PBT-1 (Fig. 3, C, D, and E). PBT-2 (Fig. 3F) and
PBT-3 (Fig. 3G) showed some inhibitory effects on BL-induced collagen
deposition in the lungs, whereas PBT-4 (Fig. 3H) showed little effect.
|
Collagen content in the right lungs of animals was greatly increased by
BL exposure, compared with saline-exposed controls (p < 0.05; Fig. 4). PBT-1 and -2 significantly (p < 0.05) reduced total collagen
compared with BL-exposed, sa-line-treated controls. PBT-3 and
-4 were not effective in preventing lung collagen deposition, which is
significantly increased relative to non-BL-exposed, saline-treated animals (p < 0.05).
|
Alveolar and interstitial macrophage content in the lung was greatly
increased by BL exposure, compared with saline-exposed controls (Fig.
5). All the HX analogs significantly
(p < 0.05) reduced the macrophage number compared with
BL-exposed, saline-treated controls. PBT-1 was also efficacious at
lower doses of 10 and 50 µg/day (p < 0.05 compared
with BL-exposed saline-treated animals; Fig. 5). PBT-2 was not as
effective as the other HX analogs in reducing macrophage number, which
are significantly increased relative to non-BL-exposed, saline-treated
animals (p < 0.05).
|
| |
Discussion |
|---|
|
|
|---|
Bleomycin, in a single dose administered intratracheally,
induces highly reproducible inflammatory and fibrotic pulmonary changes
in mice (Cooper et al., 1988
), which has been useful in directing
research toward treatment strategies for pulmonary fibrosis in humans
(Cooper, 2000
). The early lesions include diffuse alveolar hemorrhage
and marked accumulation of numerous lymphocytes, plasma cells, and
macrophages. Subsequently, increased numbers of fibroblasts secrete a
collagenous extracellular matrix that progressively thickens the
alveolar interstitium and severely compromises pulmonary function.
The mechanisms of HX protection against lung fibrosis may include the
following. First, previous studies have demonstrated an exacerbation of
the BL-evoked lung fibrosis by nordihydroguaiaretic acid (Giri and
Hollinger, 1996
), a lipoxygenase inhibitor, suggesting that some
lipoxygenase product (possibly HX) may be involved in lung protection.
Second, native HXs block the calcium-mobilizing actions (release from
intracellular stores) evoked by inflammatory mediators as diverse as
leukotriene B4, platelet activating factor, and f-met-leu-phe
(Laneuville et al., 1993
). Third, HXs possess actions on vascular
permeability (Laneuville et al., 1991
), a process that is believed to
accompany the actions of BL in causing lung fibrosis (Thrall et al.,
1979
; Adamson, 1984
). Because the native HXs are rather unstable
chemically and biologically, due to the presence of an allylic epoxide
(Demin et al., 1990
) and epoxide hydrolases in cells (Pace-Asciak et
al., 1995
), we prepared chemically stable analogs in which the unstable
epoxide is replaced by a stable cyclopropyl group (Demin and
Pace-Asciak, 1993
). These compounds mimic the actions of the native
products (C. Pace-Asciak, unpublished observations). Hence, we
speculated that the HX analogs might have anti-inflammatory actions in vivo.
Our results demonstrated that the HX analog, PBT-1, eliminated
BL-induced alveolar hemorrhage, macrophage infiltration, and collagen
deposition. The inhibitory effects of PBT-1 were evident at a dose as
little as 10 µg/day i.p. PBT-2, but not PBT-3 or -4, was also a
potent inhibitor of collagen deposition when measured in the total
lung. Of note, we found that the effects of PBT-2 on macrophage
accumulation were reduced in comparison to its high potency against
BL-induced vascular permeability in the skin and lung collagen
deposition. Since pulmonary collagen deposition induced by BL has been
suggested to involve plasma extravasation (Thrall et al., 1979
), we
believe that PBT-1 and -2, may have inhibited collagen deposition by
attenuating BL effects on vascular permeability. This may also explain
the lack of efficacy of PBT-3 and -4, which we found to be ineffective
in preventing BL-induced increased vascular permeability in the skin.
Our finding that all of the HX analogs were effective (PBT-2 less than
the others) inhibitors of macrophage influx indicate that macrophages
may not be directly related to increased vascular permeability and collagen deposition induced by BL. The precise mechanisms by which the
HX analogs exert their effects in vivo and an understanding of
structure-activity relationships of the different analogs require further elucidation. We conclude that these novel compounds warrant further investigation as potential therapeutic agents for disorders involving increased vascular permeability, inflammatory cell influx, and fibrosis.
| |
Footnotes |
|---|
Accepted for publication January 29, 2002.
Received for publication December 3, 2001.
This work was supported by Canadian Institutes of Health Research (CIHR) Grant MT-4181 (C.R.P.-A.) and a CIHR Group Grant (A.K.T.). Dr. Tanswell holds the Women's Auxiliary Chair in Neonatal Medicine. Dr. Jankov is supported by a postdoctoral fellowship from the CIHR and Canadian Lung Association, and a Clinician-Scientist training fellowship from The Hospital for Sick Children Research Institute. Dr. Luo is supported by Grant 30125019 from the National Science Fund for Distinguished Young Scholars from the Natural Science Foundation of China.
Address correspondence to: Dr. Cecil Pace-Asciak, Research Institute, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. E-mail: cecil.pace-asciak{at}sickkids.ca
| |
Abbreviations |
|---|
BL, bleomycin sulfate; HX, hepoxilin; ANOVA, analysis of variance; PBT-1, 8(S)-hydroxy-11,12-cyclopropyl-eicosa-5Z,9E,14Z-trienoic acid methyl ester; PBT-2, 8(R)-hydroxy-11,12-cyclopropyl-eicosa-5Z,9E,14Z-trienoic acid methyl ester; PBT-3, 10(S)-hydroxy-11,12-cyclopropyl-eicosa-5Z,8Z,14Z-trienoic acid methyl ester; PBT-4, 10(R)-hydroxy-11,12-cyclopropyl-eicosa-5Z,8Z,14Z-trienoic acid methyl ester; i.t., intratracheal.
| |
References |
|---|
|
|
|---|
stereospecificity of action.
Br J Pharmacol
105:
297-304[Medline].This article has been cited by other articles:
![]() |
P. J. McNamara, P. Murthy, C. Kantores, L. Teixeira, D. Engelberts, T. van Vliet, B. P. Kavanagh, and R. P. Jankov Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L205 - L213. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||